ADRISTES Trademark

Trademark Overview

On Tuesday, January 21, 2020, a trademark application was filed for ADRISTES with the United States Patent and Trademark Office. The USPTO has given the ADRISTES trademark a serial number of 88767129. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 31, 2023. This trademark is owned by Pfizer Inc.. The ADRISTES trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
adristes

General Information

Serial Number88767129
Word MarkADRISTES
Filing DateTuesday, January 21, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 31, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 5, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 25, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, July 31, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 31, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 28, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 28, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, November 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 28, 2022SOU EXTENSION 5 GRANTED
Monday, November 14, 2022SOU EXTENSION 5 FILED
Monday, November 28, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 14, 2022TEAS EXTENSION RECEIVED
Saturday, April 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 28, 2022SOU EXTENSION 4 GRANTED
Thursday, April 28, 2022SOU EXTENSION 4 FILED
Thursday, April 28, 2022TEAS EXTENSION RECEIVED
Thursday, November 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 2, 2021SOU EXTENSION 3 GRANTED
Tuesday, November 2, 2021SOU EXTENSION 3 FILED
Tuesday, November 2, 2021TEAS EXTENSION RECEIVED
Tuesday, May 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 30, 2021SOU EXTENSION 2 GRANTED
Friday, April 30, 2021SOU EXTENSION 2 FILED
Friday, April 30, 2021TEAS EXTENSION RECEIVED
Saturday, October 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 15, 2020SOU EXTENSION 1 GRANTED
Thursday, October 15, 2020SOU EXTENSION 1 FILED
Thursday, October 15, 2020TEAS EXTENSION RECEIVED
Tuesday, June 30, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 5, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 5, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 15, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, March 28, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 27, 2020ASSIGNED TO EXAMINER
Saturday, January 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 24, 2020NEW APPLICATION ENTERED

Related Keywords

adristes preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological